Oculis (OCS) Competitors $16.99 +0.16 (+0.95%) (As of 12/24/2024 01:48 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends OCS vs. BHC, VERA, KYMR, CPRX, HCM, ARWR, DYN, PTGX, AMRX, and NAMSShould you be buying Oculis stock or one of its competitors? The main competitors of Oculis include Bausch Health Companies (BHC), Vera Therapeutics (VERA), Kymera Therapeutics (KYMR), Catalyst Pharmaceuticals (CPRX), HUTCHMED (HCM), Arrowhead Pharmaceuticals (ARWR), Dyne Therapeutics (DYN), Protagonist Therapeutics (PTGX), Amneal Pharmaceuticals (AMRX), and NewAmsterdam Pharma (NAMS). These companies are all part of the "pharmaceutical products" industry. Oculis vs. Bausch Health Companies Vera Therapeutics Kymera Therapeutics Catalyst Pharmaceuticals HUTCHMED Arrowhead Pharmaceuticals Dyne Therapeutics Protagonist Therapeutics Amneal Pharmaceuticals NewAmsterdam Pharma Oculis (NASDAQ:OCS) and Bausch Health Companies (NYSE:BHC) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, community ranking, dividends, risk, earnings, media sentiment and valuation. Is OCS or BHC more profitable? Bausch Health Companies has a net margin of -1.88% compared to Oculis' net margin of -8,043.28%. Oculis' return on equity of -71.31% beat Bausch Health Companies' return on equity.Company Net Margins Return on Equity Return on Assets Oculis-8,043.28% -71.31% -56.85% Bausch Health Companies -1.88%-755.86%5.11% Do institutionals & insiders have more ownership in OCS or BHC? 22.3% of Oculis shares are held by institutional investors. Comparatively, 78.7% of Bausch Health Companies shares are held by institutional investors. 8.1% of Bausch Health Companies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has more risk and volatility, OCS or BHC? Oculis has a beta of -0.34, suggesting that its stock price is 134% less volatile than the S&P 500. Comparatively, Bausch Health Companies has a beta of 0.69, suggesting that its stock price is 31% less volatile than the S&P 500. Which has stronger valuation & earnings, OCS or BHC? Oculis has higher earnings, but lower revenue than Bausch Health Companies. Bausch Health Companies is trading at a lower price-to-earnings ratio than Oculis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOculis$980K702.21-$98.92M-$1.93-8.80Bausch Health Companies$9.47B0.29-$592M-$0.48-15.69 Do analysts rate OCS or BHC? Oculis presently has a consensus price target of $29.20, indicating a potential upside of 71.87%. Bausch Health Companies has a consensus price target of $7.75, indicating a potential upside of 2.92%. Given Oculis' stronger consensus rating and higher possible upside, analysts plainly believe Oculis is more favorable than Bausch Health Companies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oculis 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Bausch Health Companies 1 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the MarketBeat Community believe in OCS or BHC? Bausch Health Companies received 333 more outperform votes than Oculis when rated by MarketBeat users. However, 89.66% of users gave Oculis an outperform vote while only 61.47% of users gave Bausch Health Companies an outperform vote. CompanyUnderperformOutperformOculisOutperform Votes2689.66% Underperform Votes310.34%Bausch Health CompaniesOutperform Votes35961.47% Underperform Votes22538.53% Does the media favor OCS or BHC? In the previous week, Bausch Health Companies had 9 more articles in the media than Oculis. MarketBeat recorded 9 mentions for Bausch Health Companies and 0 mentions for Oculis. Bausch Health Companies' average media sentiment score of 0.89 beat Oculis' score of 0.00 indicating that Bausch Health Companies is being referred to more favorably in the news media. Company Overall Sentiment Oculis Neutral Bausch Health Companies Positive SummaryBausch Health Companies beats Oculis on 10 of the 18 factors compared between the two stocks. Ad Brownstone ResearchMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.Click here to watch this demo and decide for yourself. Get Oculis News Delivered to You Automatically Sign up to receive the latest news and ratings for OCS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OCS vs. The Competition Export to ExcelMetricOculisPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$688.16M$6.70B$5.24B$9.28BDividend YieldN/A2.98%5.12%4.28%P/E Ratio-8.8010.4287.3817.26Price / Sales702.21206.681,164.33121.12Price / CashN/A57.1543.3837.82Price / Book5.925.174.844.94Net Income-$98.92M$151.96M$121.05M$225.76M7 Day Performance-0.12%3.11%2.49%3.92%1 Month Performance10.54%-4.17%17.57%1.71%1 Year Performance54.45%7.50%28.57%15.79% Oculis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OCSOculis2.2621 of 5 stars$16.99+1.0%$29.20+71.9%+54.5%$688.16M$980,000.00-8.802BHCBausch Health Companies2.8922 of 5 stars$7.48+0.1%$7.75+3.6%+1.1%$2.71B$9.47B-15.5820,270VERAVera Therapeutics3.6611 of 5 stars$42.31-0.7%$59.22+40.0%+164.5%$2.68BN/A-16.2140KYMRKymera Therapeutics1.5138 of 5 stars$40.79+0.3%$53.88+32.1%+58.8%$2.64B$87.56M-17.43170CPRXCatalyst Pharmaceuticals4.7258 of 5 stars$21.60+1.6%$31.14+44.2%+30.4%$2.58B$460.48M18.31167Analyst DowngradePositive NewsHCMHUTCHMED2.6517 of 5 stars$14.25-0.4%$19.00+33.3%-15.1%$2.48B$420.26M0.001,988Positive NewsARWRArrowhead Pharmaceuticals4.3881 of 5 stars$19.75+1.5%$42.70+116.2%-35.3%$2.46B$3.55M-3.93400Insider TradeDYNDyne Therapeutics3.2906 of 5 stars$23.91-0.3%$50.42+110.9%+89.5%$2.43BN/A-6.72100Positive NewsPTGXProtagonist Therapeutics2.8567 of 5 stars$40.60-2.1%$53.78+32.5%+76.7%$2.42B$323.80M15.26125Positive NewsAMRXAmneal Pharmaceuticals3.0854 of 5 stars$7.79+0.1%$10.00+28.4%+36.3%$2.41B$2.68B-11.467,700Options VolumeNAMSNewAmsterdam Pharma2.8882 of 5 stars$25.63+0.5%$36.20+41.2%+135.5%$2.37B$33.59M0.0057 Related Companies and Tools Related Companies BHC Competitors VERA Competitors KYMR Competitors CPRX Competitors HCM Competitors ARWR Competitors DYN Competitors PTGX Competitors AMRX Competitors NAMS Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:OCS) was last updated on 12/26/2024 by MarketBeat.com Staff From Our Partners Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredElon Musk could help pay for your retirementElon Musk is the richest man in the world... And he's pouring trillions into a unique investment.Brownstone Research | SponsoredTSLA *BANG* incoming (bullet in the chamber rn)I just pinpointed 5 dirt-cheap stocks that could soar the second the shot goes off. Thanks to Donald Trump’...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oculis Holding AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Oculis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
